<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159594">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686594</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2012-000212-28</org_study_id>
    <secondary_id>24-169 ex 11/12</secondary_id>
    <nct_id>NCT01686594</nct_id>
  </id_info>
  <brief_title>PUVA Maintenance Therapy in Mycosis Fungoides</brief_title>
  <acronym>M_PUVA_2012</acronym>
  <official_title>A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether psoralen plus UVA (PUVA) photochemotherapy
      maintenance treatment prolongs disease-free survival of cutaneous T cell lymphoma (mycosis
      fungoides) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Psoralen plus UVA (PUVA) photochemotherapy consists of the topical or oral
      application of psoralen, followed by exposure to UVA light.  PUVA is used in various
      conditions, including early stages of mycosis fungoides (MF) and other primary and secondary
      lymphoproliferative disorders.  PUVA has strong pro-apoptotic and immunomodulating
      properties, but the exact mechanisms by which PUVA leads to clearance of MF are not well
      understood. Although MF is generally a slowly progressing disease, it ultimately can spread
      to lymphoid tissues, peripheral blood, and other organs, leading to death.

      Previous Work: PUVA therapy is a well-accepted first-line treatment option for skin-limited
      MF (stages IA, IB, and IIA), leading to complete remission in a high portion of patients
      (approximately 70 to 90%). Long-term remissions can be achieved with PUVA in a certain
      percentage of patients.  However, in most cases MF lesions relapse after stop of PUVA after
      variable time intervals with a median time to relapse of 14 to 17 month, according to our
      own experience. Not only is little is known about the therapeutic mechanisms of PUVA in MF
      but as little is known about optimal duration and frequency of treatment (2, 3, or 4 times
      weekly), dose escalation, and maintenance therapy.  Although PUVA has been introduced more
      than 30 years ago, there is lack of prospective controlled studies with clearly defined dose
      schemes and also an ongoing controversy whether PUVA maintenance therapy may prolong disease
      remission in MF upon initial complete clearance.

      Hypothesis &amp; Intended Work: We hypothesize that PUVA prolongs disease free survival in MF
      patients. In a randomized multicenter trial involving 9 centers in Austria, we plan to
      investigate (1) the clinical efficacy of PUVA and its maintenance therapy in MF and, (2) the
      mechanisms by which PUVA leads to disease clearance. In total, 82 patients will be enrolled
      and treated with a defined PUVA regimen with 2 exposures per week for 12 weeks. After 12
      weeks of PUVA treatment, patients with complete remission will be randomized into two arms.
      In Arm A patients will be treated with PUVA maintenance therapy at constant single UVA
      doses. Maintenance treatment will be given once a week for one month (4 weeks), every 2
      weeks for 2 months (8 weeks) and after three months once a month over 6 months. After 9
      months of maintenance therapy patients will discontinue therapy. Patients in Arm B will
      receive no therapy. Thereafter, all patients will be followed until recurrence or at least
      12 months (in non-recurrent patients) when the primary study analysis will be done. In
      addition, the follow-up will be extended to 60 months for long-term results.

      The mechanistic action of PUVA will be studied by laboratory investigations, including
      immune function and cytokine analysis.

      Outlook: A better understanding of the optimal regimen and the therapeutic mechanisms of
      PUVA in MF should help improving treatment strategies for this life-threatening disease. The
      understanding of the mode of action of PUVA in MF may also help to develop novel treatments
      using PUVA-affected pathways, allowing to achieve overall better long-term response and
      success.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence after complete remission within 12 months post therapy</measure>
    <time_frame>12 months after end of therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recurrence is defined as mSWAT (modified severity weighted assessment tool )  &gt;0.
The primary outcome will be evaluated by survival analysis (log-rank test; Kaplan-Meier) comparing time to recurrence after complete remission between patients treated with maintenance therapy vs. patients without maintenance therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Week -4 to 0; week 12, 24, 36, and 48; month 15, 18, 21, 24, 36, 48, 60, and 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS</measure>
    <time_frame>Week -4 to 0; week 12, 24, 36, and 48; month 15, 18, 21, 24, 36, 48, 60, and 72</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hospital anxiety depression score, compared to baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine response in serum</measure>
    <time_frame>Week -4 to 0; week 6, 12, 24, and 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of regulatory T cells</measure>
    <time_frame>Week -4 to 0; week 6, 12, 24, and 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function of regulatory T cells</measure>
    <time_frame>Week -4 to 0; week 6, 12, 24, and 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microscopic alterations</measure>
    <time_frame>Week -4 to 0; and week 6; optional at week 12, 24, and 48; and in the follow-up from year 1 to 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantification of histologic response in skin biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine expression in the skin</measure>
    <time_frame>Week -4 to 0; and week 6; optional at week 12, 24, and 48; and in the follow-up from year 1 to 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rt-PCR and immunohistochemical staining investigations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Patch/Plaque Stage Mycosis Fungoides</condition>
  <arm_group>
    <arm_group_label>PUVA maintenance treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No maintenance treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8-methoxypsoralen</intervention_name>
    <description>8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure</description>
    <arm_group_label>PUVA maintenance treatment</arm_group_label>
    <other_name>Oxsoralen®; Gerot Pharmazeutika GmbH, Vienna, Austria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically documented MF clinical stage IA-IIB (see Table1) confirmed by
             current or previous diagnostic lesion biopsy

          -  A Karnofsky performance score &gt; 60

          -  No previous PUVA treatment

          -  Anti-ds-DNA  (antinuclear antibodies) or anti-Ro/La antibodies: negative

          -  Acceptable organ function defined as follows:

        SGOT (AST) and SGPT (ALT) &lt; 2.5 times the upper limit of normal for the institution

          -  Creatinine &lt; 2 times the upper limit of normal for the institution

          -  No evidence of severe cardiac insufficiency  (NYHA grade III-IV)

          -  Women of child bearing potential must have a negative serum pregnancy test (ß-HCG)
             within seven (7) days prior to randomization

          -  Absence of any serious intercurrent illness or infection at time of entry into the
             study that could interfere with planned treatment

          -  Patients must be willing to accept limiting sun exposure on the day receiving PUVA
             treatment

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy and Lactation

          -  Photosensitive diseases such as lupus erythematosus or basal cell nevus syndrome

          -  Skin cancer syndromes such as xeroderma pigmentosum or basal cell nevus syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Wolf, MD</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>80315</phone_ext>
    <email>peter.wolf@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regina Fink-Puches, MD+</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>80428</phone_ext>
    <email>regina.fink@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Wolf, MD</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>80315</phone_ext>
      <email>peter.wolf@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Regina Fink-Puches, MD</last_name>
      <phone>+43 316 385</phone>
      <phone_ext>12371</phone_ext>
      <email>regina.fink@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regina Fink-Puches, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gudrun Ratzinger, MD</last_name>
      <phone>+43 512 504</phone>
      <phone_ext>81484</phone_ext>
      <email>gudrun.ratzinger@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Matthias Schmuth, MD</last_name>
      <phone>+43 512 504</phone>
    </contact_backup>
    <investigator>
      <last_name>Matthias Schmuth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gudrun Ratzinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, General Hospital of the City of Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josef Auböck, MD</last_name>
      <phone>+43 732 7806</phone>
      <phone_ext>3732</phone_ext>
      <email>josef.auboeck@akh.linz.at</email>
    </contact>
    <contact_backup>
      <last_name>Christine Scheurecker, MD</last_name>
      <phone>+43 732 7806</phone>
      <phone_ext>3732</phone_ext>
      <email>christine.scheurecker@akh.linz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Josef Auböck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Scheurecker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne Gross, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Hospital Salzburg - Paracelsus Private Medical University</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helmut Hintner, MD</last_name>
      <phone>+43 662 4482</phone>
      <phone_ext>3001</phone_ext>
      <email>h.hintner@salk.at</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia Selhofer, MD</last_name>
      <phone>+43 662 4482</phone>
      <phone_ext>3001</phone_ext>
      <email>S.Selhofer@salk.at</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Hintner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvia Selhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, County Hospital St. Pölten</name>
      <address>
        <city>St. Pölten</city>
        <zip>A-3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franz Trautinger, MD</last_name>
      <phone>+43 2742 300</phone>
      <phone_ext>11906</phone_ext>
      <email>franz.trautinger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Eder, MD</last_name>
      <phone>+43 2742 300</phone>
      <phone_ext>11906</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Franz Trautinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne Eder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>A-1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul-Gunther Sator, MD</last_name>
      <phone>+43 1 80110</phone>
      <phone_ext>2422</phone_ext>
      <email>paul.sator@wienkav.at</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Steiner, MD</last_name>
      <phone>+43 1 80110</phone>
      <phone_ext>2422</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Andreas Steiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul-Gunther Sator, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Tanew, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>7710</phone_ext>
      <email>adrian.tanew@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Anja Pinkowicz, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>7710</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Adrian Tanew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anja Pinkowicz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Klinikum Wels</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Werner Saxinger, MD</last_name>
      <phone>+43 7242 415</phone>
      <phone_ext>9 2105</phone_ext>
      <email>werner.saxinger@klinikum-wegr.at</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Fleischanderl, MD</last_name>
      <phone>+43 7242 415</phone>
      <phone_ext>9 2105</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Werner Saxinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Fleischanderl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, County Hospital Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>A-2700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Muellegger, MD</last_name>
      <phone>+43 2622 321</phone>
      <phone_ext>4901</phone_ext>
      <email>robert.muellegger@wienerneustadt.lknoe.at</email>
    </contact>
    <contact_backup>
      <last_name>Nicolaus Sandor, MD</last_name>
      <phone>+43 2622 321</phone>
      <phone_ext>4901</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Robert Muellegger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolaus Sandor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>May 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycosis fungoides</keyword>
  <keyword>Psoralen and UVA (PUVA)</keyword>
  <keyword>Photochemotherapy</keyword>
  <keyword>Maintenance treatment</keyword>
  <keyword>Immune function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methoxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
